Royalty Report: Drugs, Cancer, Antibody – Collection: 260380

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 20

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 20

Primary Industries

  • Drugs
  • Cancer
  • Antibody
  • Therapeutic
  • Disease
  • Drug Discovery
  • Surgical
  • Wound Care
  • Diagnostic
  • Technical Know How
  • cell therapy
  • Biotechnology
  • Medical
  • Assay
  • Cell Line

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 260380

License Grant
For the Licensed Technology, the Licensor, of the Netherlands,  grants a non-exclusive, non-transferable, right and license, with the right to grant sublicenses, under the Licensed Technology, to make, have made, use, have used, offer for sale, have offered for sale, sell, have sold, import and have imported the Products in the Territory and the Field.

For the Evaluation License, Licensor grants a nonexclusive, non-transferable, worldwide right and license, with rights to sublicense, for the Term of this Agreement, under all intellectual property rights owned or controlled by Licensor as of the Effective Date or at any time during the Term, to evaluate the Secondary Assets, and all materials and information relating thereto, including without limitation the Secondary Asset Preliminary Materials, solely for the purposes of determining whether Licensee desires to exercise the Option with respect to any such Secondary Assets.

License Property
Licensor owns certain proprietary cell lines producing biosimilar monoclonal antibodies to Trastuzumab, Bevacizumab and Rituxirnab.

Product means any antibody product, including, without limitation, fragments thereof, produced by Licensee, its Affiliates or sublicensees from the Assets.

Primary Asset means CHOBC® cell lines producing the biosimilar monoclonal antibody Trastuzumab; unmodified descendants of those cell lines;  unmodified subunits, including without limitation subclones, purified or fractionated subsets thereof; and, material that contains or incorporates any of the above.

Secondary Assets means the Bevacizumab Asset and the Rituximab Asset.

Bevacizumab Asset means CHOBC® cell lines producing biosimilar monoclonal antibodies to Bevacizumab; unmodified descendants of those cell lines;  unmodified subunits, including without limitation subclones, purified or fractionated subsets thereof; and, material that contains or incorporates any of the above.

Rituximab Asset means CHOBC® cell lines producing biosimilar monoclonal antibodies to Rituxhnab; unmodified descendants of those cell lines;  unmodified subunits, including without limitation subclones, purified or fractionated subsets thereof; and, material that contains or incorporates any of the above.

Field of Use
The Field means any and all fields.  The Licensee, following a merger,  became a commercial-stage biotechnology company focused on improving patient access to important biopharmaceuticals by developing, manufacturing, and commercializing biosimilar therapeutics, or biosimilars, in targeted geographies worldwide.

Bevacizumab is a medication used to treat a number of types of cancers and a specific eye disease. For cancer it is given by slow injection into a vein and used for colon cancer, lung cancer, glioblastoma, and renal-cell carcinoma.

Rituximab is a chimeric monoclonal antibody against the protein CD20, which is primarily found on the surface of immune system B cells.

Trastuzumab is a monoclonal antibody used to treat breast cancer. Specifically it is used for breast cancer that is HER2 receptor positive.

IPSCIO Record ID: 260381

License Grant
For the Licensed Technology,  Licensor of the Netherlands grants a non-exclusive, non-transferable, right and license, with the right to grant sublicenses, under the Licensed Technology, to make, have made, use, have used, offer for sale, have offered for sale, sell, have sold, import and have imported the Products in the Territory and the Field.

For the Sublicenses, the rights and license granted, as applicable, include the right to grant sub licenses to sublicensees of Licensees technology platform, including without limitation, partners in Licensees In Market, For Market Program, pursuant to a binding written agreement between Licensee and such sublicensee that is consistent with the terms and conditions of this Agreement.

For the Technology Transfer, Licensor, utilizing Licensors usual and customary means of shipment of similar materials, shall deliver to Licensee Viable Cells of the Asset CHOB c® cell line and related Know-How, including without limitation reasonable written documentation with respect to the transport, storage and use of the Asset and safety information thereto.

For the Ownership of Platform, Licensor grants to an exclusive, perpetual, irrevocable, sublicenseable through multiple tiers,  license under any and all such, Joint Inventions, and any and all intellectual property rights therein, to make, have made, use, have used, offer for sale, have offered for sale, sell, have sold, import and have imported the Products in the Territory and the Field.

License Property
Licensor owns certain proprietary cell lines producing biosimilar monoclonal antibodies to Adalimumab, a proposed biosimilar to Humira.

Licensors CHOBC® Platform means Licensors proprietary CHOBC® cell line platform, together will all inventions, tangible materials, associated know how, data and other information (and all Intellectual Property Rights associated therewith) that are developed by Licensor before the Effective Date or thereafter, to the extent they relate to the CHOBC® cell line and are useful for the development and/or manufacture of biosimilar monoclonal antibodies.

Asset means, as of the Effective Date,  CHOBC® cell lines producing biosimilar monoclonal antibodies to Adalimumab;  unmodified descendants of those cell lines;  unmodified subunits, including without limitation subclones, purified or fractionated subsets thereof; and material that contains or incorporates any of the above.

Field of Use
The Field means any and all fields.  Adalimumab is marketed and used to treat inflammatory diseases.

Prior to the Merger, the Licensee was a biopharmaceutical company developing drug candidates with a focus on the treatment of pain. Following the Merger, Licensee became a commercial-stage biotechnology company focused on improving patient access to important biopharmaceuticals by developing, manufacturing, and commercializing biosimilar therapeutics, or biosimilars, in targeted geographies worldwide.

IPSCIO Record ID: 91093

License Grant
Licensor grants the sole and exclusive license to the Chinese Licensee for the territory, with rights to sublicense, to research, develop, make, have made, use, sell, market, offer for sale, and import or export products and/or services in any and all fields and forms of use or application.

On June 30, 2016, the Company reached an agreement for the settlement of outstanding accounts payable and cell line transfer with its manufacturer. On July 7, 2016, this sum was paid to the manufacturer. In addition to resolving its outstanding account payable to the manufacturer, the Company will receive credits toward (i) completion of the product testing and manufacturing report, (ii) the cell line transfer fee; and (iii) the royalty on licensed sales.

License Property
Licensor owns or has rights to the human monoclonal antibody Pritumumab along with certain patents, technology, information,Know-how, and materials related to this antibody, including, without limitation, the Master Cell Bank for the GPEx cell line employed to produce the Pritumumab antibody.  Pritumumab is a monoclonal antibody for the treatment of epithelial cancers (which include brain, pancreas, colon, lung and breast).
Field of Use
The field of use means all human therapeutic, prophylactic, and diagnostic uses of the human monoclonal antibody Pritumumab and the GPEx cell line for cancer and other diseases.

IPSCIO Record ID: 369249

License Grant
Licensor grants an exclusive, worldwide, license, with the right to sublicense, under the Licensor Technology to research, develop, make, have made, use, sell, offer for sale and import Licensed Products solely in the Antibody Targeting Technology Field.

Licensor grants an exclusive, worldwide, license, with the right to sublicense, under the HuMAb Technology and the Licensor Technology to research, develop, make, have made, use, sell, offer for sale and import
— Licensed Royalty-Bearing Products solely in the Antibody Targeting Technology Field, and,
— Anti-Mannose Products.

For Hybridoma Cell Lines; Research License, Licensor grants an exclusive, worldwide license, with the right to sublicense, under the HuMAb Technology to research, make, have made, transfer physical possession of, but not to sell, lease, offer to sell or lease, or otherwise transfer title to, the Hybridoma Cell Lines.

Licensor grants a non-exclusive, worldwide, license, with the right to sublicense, under the Research Patent to conduct research.

For Research Antibodies License, Licensor grants an exclusive, worldwide license, without the right to sublicense, under the HuMAb Technology and the Licensor Technology to use the Research Antibodies for the sole purpose of determining the antigen with respect to which each Research Antibody was raised.

Licensor, who has incorporated Licensee for business opportunities outside of Licensors core business, irrevocably, perpetually and forever assigns and conveys Licensors entire right, title and interest in and to each of the following Assigned Assets
— Antibody Targeting Patents;
— Antibody Targeting Know-How;
— Anti-Mannose Receptor HuMAb Antibodies;
— the Investigational New Drug Application # 11,508 and related governmental filings, and the right to make any future or foreign related filing on –X-1307;
— all quantities of Biological Materials, including those in the possession or control of counterparties to Assigned Contracts;
— all clinical inventories of –X-1307 in the possession or control of Licensor as of the Effective Date; and
— the agreements that are Assigned Contracts.

License Property
Licensor owns or otherwise controls certain technology, including certain patents and know-how, relating to the use of antibodies in connection with the research and development of vaccines.

Anti-Mannose Product shall mean any pharmaceutical composition or formulation incorporating an Anti-Mannose Receptor HuMAb Antibody.

HuMAb Mouse® shall mean any of Licensors immunizable transgenic mice containing unrearranged human immunoglobulin heavy and light chain transgenes, each inserted into mouse chromosomes, but excluding the Additional Mice. HuMAb Mice® shall mean more than one HuMAb Mouse.

The patents relate to Anti-FcyRI (CD64) antibodies.

Field of Use
The field of use is the Antibody Targeting Technology Field.  The Antibody Targeting Technology Field shall mean the use of an antibody, or fragment thereof, whereby the antibody or fragment serves as a targeting means with respect to an Antigen-Presenting Cell for the purpose of modulating an immune response in any of the following manners
—  an antibody or fragment chemically attached or genetically fused to an antigen (including an antigen that is an antibody, or fragment thereof, that encodes an idiotype antigen), whereby the antibody, or fragment thereof, serves as a targeting means for delivering such antigen to an Antigen-Presenting Cell for the purpose of eliciting an immune response,
— an antibody or fragment chemically attached or genetically fused to a toxin or radionuclide, whereby the antibody, or fragment thereof, serves as a targeting means for delivering such toxin or radionuclide to an Antigen-Presenting Cell for the purpose of decreasing, down-regulating or eliminating the activity of such Antigen-Presenting Cell,
— an antibody or fragment chemically attached or genetically fused to a cytokine, adjuvant, or other immuno-modulatory compound, whereby the antibody, or fragment thereof, serves as a targeting means for delivering such compound to an Antigen-Presenting Cell for the purpose of modulating the activity of such Antigen-Presenting Cell, and
— an antibody, or fragment thereof, alone, whereby the antibody or fragment binds to a particular antigen on the surface of an Antigen-Presenting Cell and through such binding modulates the activity of such Antigen-Presenting Cell.

IPSCIO Record ID: 211863

License Grant
Licensor is the assignee of all right, title and interest in the Patent Rights, Biological Materials and Know-How from a third party.

Pursuant to the third partys permission, for the nonexclusive license, Licensor grants the worldwide, nonexclusive right and license, with the right to sublicense, in the Field under the Patent Rights to make, have made, use, lease, sell, offer for sale and import the Licensed Products and to practice the Licensed Processes; to make, have made, use, lease, sell, offer for sale, import and create Modifications of the Biological Materials; and to use Know-How, and

For the exclusive license, Licensor grants the worldwide, exclusive right and license, with the right to sublicense, in the Field to make, have made, use, lease, sell, offer for sale and import Modifications.

License Property
The licensed products include among other things, Progeny, an unmodified descendant from the Biological Materials, such as virus from virus, cell from cell, or organism from organism.   Some examples include subclones of unmodified cell lines, purified or fractionated subsets of the Biological Material(s), proteins expressed by DNA/RNA supplied by Licensor, or monoclonal antibodies secreted by a hybridoma cell line.
Field of Use
The Field shall mean IN VIVO human and veterinary medical use of polymers falling within the Patent Rights, including, without limitation, tissue engineering, cell therapy, implantables, medical devices, wound sealants, prescription and non-prescription drug delivery, and contrast agents, but excluding medical disposables, surgical drapes and trays, sanitary products, barrier contraceptives, nutritional and all other diagnostic uses and transgenic plant crop production of polymers.

IPSCIO Record ID: 256273

License Grant
The German Licensor grants the Swiss Licensee a worldwide, exclusive, right and license, or sublicense, with the right to grant sublicenses, under the Licensed Technology to make, have made, use, offer for sale, sell, and import the Product in the Field in the Territory.

This agreement includes a non-exclusive grant by Licensee to Licensor.

License Property
Licensor is developing a pharmaceutical product comprising a human antibody of IgG-1 subtype binding to EpCAM.

The patents include Novel Method for the Production of anti-human Antigen Receptors and Uses thereof, and, Anti-EpCAM Immunoglobulins.

Decatumumab (MT201) is a recombinant human monoclonal antibody with a binding specificity to epithelial cell adhesion molecule (Ep-CAM). Adecatumumab (MT201) is being evaluated in two European Phase 2 clinical trials, one in patients with prostate cancer, and one in patients with metastatic breast cancer.

Field of Use
The Field means the treatment of human diseases, disorders and conditions.

IPSCIO Record ID: 27645

License Grant
Japanese Licensor grants to Licensee and its Affiliates the sole and exclusive, world-wide, royalty-bearing, assignable license under the Licensed Patents and Related Materials, with right to sublicense in one or more tiers of sublicenses, to research, develop, make, have made, use, sell, offer for sale, and import products and/or services in any and all fields of use or application.
License Property
Licensor owns certain rights in and to certain patents, information and materials related to the human antibody Pritumumab and a sister antibody to Pritumumab.

Licensed Patents
Patents on pritumumab (aka, CLNH11/CLNIgG; plus CLNH5)
4,618,577 – human-human hybridoma, CLNH5

4,761,377 – human-human hybrid cell lines that produce antibodies against antigenic determinants on cancer cells

5,093,261 – cancer-related antigen-specific human immunoglobulins and human/human hybridomas having the ability to produce said human immunoglobulins

5,155,036 – serum-free medium containing retinoic acid useful for cultivating human/human hybridomas

5,286,647 – human-human hybridomas for neoplasms

5,589,573 – amino acid sequences of anti-idiotypic antibodies against anti-cancer human monoclonal antibody, and DNA base sequences encoding those sequences.

5,602,027 – cell line TRIH8 obtained by the fusion of the human epidermoid carcinoma cell line A431 with the TOS/H8 hybridoma.

6,051,229 – human-humann hybridoma for neoplasms CLNH5 and CLNH11 specific antibody compositions

6,051,387 – methods of determining the presence of a neoplasm with CLNH5- and CLNH11-specific antibodies

6,051,693 – CLNH11-specific antibodies

6,090,924 – human-human CLNH5-specific antibodies

6,165,467 – stabilized human monoclonal antibody preparation

Field of Use
Pritumumab is a human monoclonal antibody[1] used in the treatment of brain cancer.

The goal of the Licensee is to become a leading oncology-focused biopharmaceutical company

IPSCIO Record ID: 344584

License Grant
Licensor grants an exclusive, worldwide license under any and all patents, copyrights, trademarks, trade secrets, know-how and other intellectual property and other proprietary rights Licensor has or may have in and to the Antibody to manufacture, have manufactured, use, sell, offer to sell and import Licensed Products.
License Property
Licensor, through a wholly-owned subsidiary, has certain expertise and technology relating to the creation of chimeric antibodies.

Licensed Products means all products incorporating the Antibody.

The Antibody means the chimeric antibody and the chimeric antibody producing cell line created by Licensors Subsidiary, pursuant to the Project and fragments, or direct or indirect derivatives or mimetics or chimeric constructs thereof, and samples of biochemical, biological, clonal, or synthetic chemical materials or sequence data relating thereto and regardless of whether such chimeric antibodies or cell lines were subsequently modified by Licensee, Licensees Affiliate or any Third Party.

Field of Use
Licensee is a biopharmaceutical company primarily engaged in the research, development, manufacture and commercialization of cancer therapeutics and cancer diagnostics through a series of proprietary platform technologies using monoclonal antibodies.

IPSCIO Record ID: 325366

License Grant
Through a partnership with a third party, Licensee develops and/or commercialize sugemalimab for worldwide sales which results in royalty payments to Licensor.
License Property
Sugemalimab (CS1001), an OmniAb-derived anti-PD-L1 monoclonal antibody used in combination with chemotherapy for lung cancer.
Field of Use
Field of use is for the first-line treatment of advanced squamous and non-squamous non-small cell lung cancer (“NSCLC”).

Lung cancer is a type of cancer that starts in the lungs. Cancer starts when cells in the body begin to grow out of control. The main subtypes of NSCLC Lung Cancer are adenocarcinoma, squamous cell carcinoma, and large cell carcinoma.

IPSCIO Record ID: 203293

License Grant
Licensor is the assignee of all right, title and interest in the Patent Rights, Biological Materials and Know-How from a third party.

Pursuant to the third partys permission, for the nonexclusive license, Licensor grants the worldwide, nonexclusive right and license, with the right to sublicense, in the Field under the Patent Rights to make, have made, use, lease, sell, offer for sale and import the Licensed Products and to practice the Licensed Processes; to make, have made, use, lease, sell, offer for sale, import and create Modifications of the Biological Materials; and to use Know-How, and

For the exclusive license, Licensor grants the worldwide, exclusive right and license, with the right to sublicense, in the Field to make, have made, use, lease, sell, offer for sale and import Modifications.

License Property
The licensed products include among other things, Progeny, an unmodified descendant from the Biological Materials, such as virus from virus, cell from cell, or organism from organism.   Some examples include subclones of unmodified cell lines, purified or fractionated subsets of the Biological Material(s), proteins expressed by DNA/RNA supplied by Licensor, or monoclonal antibodies secreted by a hybridoma cell line.
Field of Use
The Field shall mean IN VIVO human and veterinary medical use of polymers falling within the Patent Rights, including, without limitation, tissue engineering, cell therapy, implantables, medical devices, wound sealants, prescription and non-prescription drug delivery, and contrast agents, but excluding medical disposables, surgical drapes and trays, sanitary products, barrier contraceptives, nutritional and all other diagnostic uses and transgenic plant crop production of polymers.

IPSCIO Record ID: 383584

License Grant
Licensor grants a worldwide exclusive right and license under Know-how, with the right to sublicense others, to make, have made, use, sell, offer for sale and import Licensed Products.

Licensor grants an exclusive license under Patent Rights, with respect to Licensors fifty percent ownership interest in such Patent Rights, with the right to sublicense others, to make, have made, use, sell, offer for sale and import Licensed Products in all jurisdictions outside the United States.

License Property
Licensed Products shall mean Erbitux®, and matuzumab  as well as all derivatives, analogs, fragments, improvements, conjugates and bioequivalents of any of the foregoing.

Erbitux® shall mean cetuximab, and marketed as Erbitux®.

ERBITUX (cetuximab) is an epidermal growth factor receptor (EGFR) inhibitor. EGFR is a receptor found on both normal and tumor cells that is important for cell growth.

The patent is titled Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same.

Field of Use
Erbitux ( cetuximab) is a cancer medicine that interferes with the growth and spread of cancer cells in the body.

IPSCIO Record ID: 266792

License Grant
The Israeli Licensor, the technology transfer company of the University, grants an exclusive license, with the right to sublicense in two tiers, under All Patents to make, have made, use, sell, offer for sale and import the licensed products.

With this agreement, the Parties wish to resolve all existing and potential claims and outstanding obligations in connection with All Litigation Matters and desire to settle All Litigation Matters on the terms stated herein, without any admission of liability or wrongdoing, in order to avoid the time and expense of continuing to litigate All Litigation Matters.

License Property
The licensed products and related patents are for cetuximab _-C225 (Erbitux®), _-11F8 and all product incorporating the humanized antibody of  ___72000.

Cetuximab is an antibody for use in combination with irinotecan in the treatment of patients with epidermal growth factor receptor (EGFR)-expressing, metastatic colorectal cancer who are refractory to irinotecan-based chemotherapy and for use as a single-agent in the treatment of patients with EGFR-expressing, metastatic colorectal cancer who are intolerant to irinotecan-based chemotherapy.

11F8 is a fully-human monoclonal antibody which targets the human EGFR.

__-72000, also known as matuzumab, is a humanized EGFR-targeting monoclonal antibody.

Field of Use
Licensor is a biopharmaceutical company advancing oncology care by developing and commercializing a portfolio of targeted treatments designed to address the medical needs of patients with cancer.

IPSCIO Record ID: 227273

License Grant
For the Exclusive License, Licensor grants an exclusive, worldwide license, including the right to sublicense, to the Licensor Technology, and any Improvements and Joint Improvements thereto, including a bailment to possess the Licensed Antibodies and Property Rights and transfer possession of the same under a valid sub license, to make, to have made, to import, to export, to use, to offer for sale, and to sell Licensed Products.

For the Non-Exclusive License to Joint Improvements, In the event that this Agreement is terminated or expires for any reason, Licensor shall automatically grant to Licensee a non-exclusive, perpetual, worldwide license, including the right to sublicense, to any Joint Improvements, which non-exclusive license shall survive and termination or expiration of this Agreement.

License Property
The term Property Rights shall mean all of M-Techs or its Affiliates property rights to the biological material described as the L56, L72 and L33 cell lines and the monoclonal antibodies.

The L56 cell line is a cultured human B-lymphoblastoid cell line that Produces a human IgM monoclonal antibody (L56 FiuMAb ).

The L72 cell line is a cultured human B lymphoblastoid cell line that produces a human IgM monoclonal antibody to ganglioside GD2 (L72HuMAb).

The L33 cell line is a cultured human B-lymphoblastoid cell line that produces a human IgM monoclonal antibody to heat shock protein 27 (L33HuMAb ).

The term 20 Cell Lines shall mean the twenty tumor cell lines listed in of this Release Agreement, including all progeny, modified and unmodified derivatives, secretions and antigens thereof.

Field of Use
Licensor is engaged in the discovery, development and commercialization of biological products for the treatment, prevention and control of cancer.

IPSCIO Record ID: 357950

License Grant
Licensor grants to Licensee, an affiliate, an exclusive, worldwide right and license, with the right to sublicense, under the Licensed Patents to research, Develop, manufacture, have manufactured, use, import and Commercialize and have Commercialized the Licensed Products, in and for the Field and to practice and have practiced any Licensed Processes, in and for the Field.

Effective immediately at the time Licensee is no longer deemed to be an Affiliate of Licensor, Licensor grants Licensee a non-exclusive license under Licensed rights in and to the Licensed Materials solely in support of the exercise of Licensees license rights.  Licensee shall not have the right and shall be prohibited from selling, transferring, or distributing the Licensed Materials to end users, except in the case where such end users are Licensor Affiliates or Sub licensees under this Agreement.

License Property
Licensor has rights to the Licensed Patents and Materials as granted by Dana Farber Cancer Institute.

Antibody means any antibody, any gene expressing such an antibody, any hybridoma producing such antibody, or any fragment, variant, derivative or construct thereof, or antibody fusion protein produced therefrom, including PEDgylated or multimeric versions thereof, whether polyclonal, monoclonal, multi-specific antibodies, e.g., bi-specific antibodies, human, humanized, chimeric, murine, synthetic, or from any other source, including without limitation, the full immunoglobin molecules (e.g. the IgG, IgM,IgE, IgA, and IgD molecules), and the antigen binding portions including Fab, Fab, F(ab)2, Fv, dAb, and CDR fragments, chimeric antibodies, diabodies, polypeptides, linear antibodies and single-chain antibodies (scFv) that contain any portion of an immunoglobulin that is sufficient to confer specific binding to an antigen.

The agreement is to develop and commercialize Licensor's fully human anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies.

Field of Use
The Field means all prophylactic, palliative, therapeutic or diagnostic uses in humans or animals for the prevention, diagnosis and treatment of hematological malignancies, including, without limitation, all Leukemias, Lymphomas, Multiple Myeloma and Waldentroms Macroglobulemia, but specifically excluding use in chimeric antigen receptor technology. Additionally, upon exercise of the Autoimmune Option, the Field shall include the prevention, diagnosis and treatment of Autoimmune Diseases.

Autoimmune Diseases means any disease which results from a loss of immune tolerance to self-antigens, including without limitation multiple sclerosis, rheumatoid arthritis, systemic lupus erythematosus, sjogren syndrome, celiac disease, Graves disease, myasthenia gravis, Type I diabetes, idiopathic thrombocytopenic purpura, pemphigus vulgaris, among others, including any presentation or manifestation thereof.

IPSCIO Record ID: 245920

License Grant
Licensor grants an exclusive license in the Territory under the Licensor Technology solely for the purpose of conducting research and development activities on the Research Antigens and evaluating EOSs interest to exercise the Options.

Licensor grants an exclusive Option for each Research Antigen designated to obtain the Exclusive License set forth during the Option Period.

If Licensee elects to exercise its option to acquire an Exclusive License with respect to a particular Research Antigen, and Licensee pays the Option Exercise Fee, then subject to the terms and conditions of this Agreement, and commencing as of the date that Licensor has received the Option Exercise Fee from Licensee, Licensor is automatically deemed to grant, and in such event hereby grants, to Licensee, on a Research Antigen-by-Research Antigen basis, a worldwide, exclusive, even as to Licensor, nontransferable, royalty-bearing license under the Licensor Technology, with the right to sublicense, to discover, have discovered, to develop, have developed, make, have made, import, have imported, export, have exported, use, sell and have sold Products directed toward such Research Antigen within the Field in the Territory.

License Property
Licensor owns or controls intellectual property rights relating to certain drug conjugation and linker technology.

The licensors patents and technology are for Antibodies, Research Antigens, Exclusive Antigens, and Jointly-Invented Inventions Related thereto.

Antigen means any protein, including any glyco- or lipo-protein, carbohydrate, compound or other composition, and any fragment, peptide or epitope thereof, to which an antibody hinds.

Product means any and all products where the manufacture, sale or use of such products would have constituted a misappropriation of Drug Conjugation Technology, Licensor Know-How, Improvements or New Technologies, and/or an infringement of the Licensed Patents but for the licenses granted in this Agreement.

The binding of an antibody to the surface of a cancer cell rarely induces cell death by itself.  Enhancing the potency of antibodies through the linkage of drug payloads provides a means to selectively kill cancer cells while limiting damage to normal tissue.

Field of Use
The Parties will collaborate to use Licensor's toxic payload technology with Licensee's proprietary monoclonal antibodies directed against novel cancer targets derived from their analyses of the human genome.

IPSCIO Record ID: 109479

License Grant
Pursuant to this agreement, to use the Mice to evaluate their utility for the development of fully human monoclonal antibodies to the human CRl complement receptor (CRl) and Staphylococcus aureus, Licensee has the right to exercise an option for a commercial license where Licensor shall grant the following licenses
(a) an exclusive, worldwide, non-transferable license under the Licensors Technology to use the Mice to make Antibodies, and
(b) an exclusive, worldwide license under the Licensors Technology, with the right to sublicense, to use such Antibodies to make, have made, import, have imported, use, offer for sale and sell Products.
License Property
Licensor is the sole and exclusive owner of certain transgenic Mice useful for the preparation of fully human monoclonal antibodies.

Antibody means a human monoclonal antibody with binding affinity for an Antigen derived by Licensee or its Affiliates or Sublicensees from cells obtained from one or more of the Mice.

Product shall mean any product for the treatment of human disease containing an Antibody with affinity for CRI, or a bispecific antibody consisting of a combination of an Antibody with affinity for CRI and an Antibody to Staphylococcus aureus.

'Mice' shall mean immunizable sterile transgenic mice containing unrearranged human immunoglobulin genes.

Field of Use
This agreement is for the biotechnology industry.  Licensee wishes to acquire from Medarex an option to acquire a commercial license for the use of such monoclonal antibodies to commercialize Products.

IPSCIO Record ID: 291107

License Grant
Collaborator hereby grants to Licensee of Ireland an exclusive license (exclusive even as to Collaborator), with the right to sublicense, under the Collaborator Technology, to use, have used, Develop, have Developed, Manufacture, have Manufactured, Commercialize and have Commercialized Antibodies and Products in the Territory.
License Property
Product means any pharmaceutical product containing one or more Antibodies whose manufacture, use, sale, offer for sale or importation by Licensee in a given country in the Territory is covered by a Valid Claim under a Collaborator Patent Right or Sponsored Research Patent Right in such country.

Collaborator Patent Right means any Patent Right that (a) is Controlled by Collaborator or any of its Affiliates as of the Effective Date (including the Collaborator Patent Rights that comes into the Control of Collaborator or any of its Affiliates during the Term (other than through the grant of a license by Licensee) and (b) claims or discloses any (i) Antibody or Product (including the composition of matter thereof), (ii) method of making any Antibody or Product or materials used in any method of making any Antibody or Product, or (iii) methods of using any Antibody or Product.

Collaborator Technology means the Collaborator Patent Rights and Collaborator Know-How.

Patent Rights means any and all (a) issued patents, (b) pending patent applications, including all provisional applications, substitutions, continuations, continuations-in-part, divisions and renewals, and all patents granted thereon, (c) patents-of-addition, reissues, reexaminations and extensions or restorations by existing or future extension or restoration mechanisms, including patent term adjustments, patent term extensions, supplementary protection certificates or the equivalent thereof, (d) inventor’s certificates, (e) other forms of government-issued rights substantially similar to any of the foregoing and (f) United States and foreign counterparts of any of the foregoing.

1. The Identification and Selection of individual Human B cell donors
Pre-requisites to I-STAR screen
• Initiate blood (B cell) collection program for non-small cell lung carcinoma.
• 200 donors to be screened serologically prior to selection for I-STAR memory B cell activation.
• Perform serum binding assay against NSCLC tumor cell lines.
• Selection of top 50 subjects/ B cell donors with serum reactivity against NSCLC tumor cell lines for IgG+ memory B cell isolation and activation (I-STAR platform). Subject selection to be done by Pfizer/ Theraclone joint project team.

2. I-STAR process for selection of native human bNAbs
I-STAR Antibody Discovery Platform
• Perform activation of short-term memory B cell cultures (B cell expansion and differentiation) from a total of 50 selected individuals.
• 2000-20,000 native human memory B cell clones from each of  50 selected donors to be activated in vitro in preparation for screening assay.
• Perform a two step screening process to identify NSCLC binding antibodies.
o Primary screening by a high-throughput cell binding assay with NSCLC tumor cell lines using supernatant from cultured B cells. Primary screens will provide initial identification of antibody binding of up to 10 tumor cell lines. The NSCLC tumor cell lines will be chosen by the Pfizer/ Theraclone joint project team. Screening will utilize pools of three to four tumor cell lines to increase throughput.
o Perform secondary screens on tumor cell line binding antibodies. Secondary screens will assess binding to NSCLC tumor cell lines by suitable techniques, and lack of binding to a normal cell line. Normal cells lines will be chosen by the joint project team.
• Deep sequencing of up to 2,880 hit wells to be performed and sequence analysis allowing clustering of hits into bins (based on V-region (VH / VL sequences). All DNA and amino acid sequences delivered to Pfizer.
• Joint project team to prioritize up to 200 mAbs for small scale expression.

3. Generation of recombinant mAh protein and re-screening against target cells
• Generation (expression and purification) of transiently transfected full-length, human mAbs from mammalian cells in an appropriate human IgG format for up to 200 target antigen positive V-region hits.
• Initial characterization of recombinant mAbs to confirm NSCLC tumor cell line binding, internalization and binding to disaggregated cells from PDX tissue.
• Develop an internalization assay based on cell killing by auristatin conjugates. Several antibodies, including anti-EGFR, anti-HER2, anti-transferrin receptor and TCN-462 will be evaluated as potential internalization control antibodies.

4. Generation of large scale recombinant mAh protein, characterization data and re-screening against targets
• Selection of up to 50 unique antibodies that the joint project team regards suitable for further analysis
• Selection criteria
o Binding to NSCLC PDX tissue
o Binding to cancer cells in vitro, Ko determination by tumor cell binding
o Lack of binding to normal cell lines
o Internalization into NSCLC tumor cell lines
• mAb expression and purification at Theraclone – highest 50 prioritized mAbs at 5 – 20 mg scale. Additional prioritized mAbs purified at 5-20 mg scale subject to joint project team approval.
• Quality control A280, SDS-PAGE, CIEX, SEC, target I antigen binding profile, endotoxin analysis

Field of Use
I-STAR technology relates to discover broadly protective monoclonal antibodies against up to four undisclosed targets in the areas of infectious disease and cancer.

IPSCIO Record ID: 163133

License Grant
Licensor grants a Sublicense to Licensee and its Affiliates, to use the Licensor Antibodies, Cell Lines and Derivatives for the purpose of making, having made, using, selling and having sold Licensee Products.  Licensor shall provide Licensee quantities of Licensor Antibodies or Cell Lines and Derivatives, and information relating thereto.  Licensor agrees to deliver additional viable aliquots of Cell Lines or Derivatives to replace any aliquots previously delivered, which have subsequently become incapable of producing Licensor Monoclonal Antibodies and which are the same as the Licensor Cell Lines or Derivatives previously received by Licensee.

In order to protect Licensees source of supply of the Cell Lines or Derivatives Licensor warrants and agrees that Licensor shall maintain the Cell Lines and Derivatives in such a manner as will best preserve the viability thereof, in accordance with established scientific procedures.

License Property
Licensor holds exclusive licenses with respect to the Antibodies. Licensor is a supplier of specialty reagents, immuno-assay test kits and molecular research products to customers involved in biomedical research, the biotechnology industry and pharmaceutical drug discovery.

Monoclonal Antibodies to Human Interferongamma
        *1.       Antibody B133.5

         2.       Antibody 3C11C8

         3.       Antibody 2G1

Monoclonal Antibodies to Human Granulocyte Marophage-Colony Stimulating Factor

         1.       Antibody 3092

         2.       Antibody 3034

         3.       Antibody 1089

         4.       Antibody 4117

         5.       Antibody 2118

         6.       Antibody 1028

Monoclonal Antibodies to Human Tumor Necrosis Factor-alpha

         *1.      Antibody B154.7.1

         *2.      Antibody B154.9.1

Field of Use
The purpose for this agreement is for research use.

IPSCIO Record ID: 369305

License Grant
Licensor, a nonprofit cancer research institute, hereby grants to Licensee and Licensee accepts subject to the terms and conditions hereof the following licenses
(a) a non-exclusive license to use, possess, culture and employ the Licensed Cell Line at its business premises solely in the United States;
(b) a worldwide, non-exclusive license to the Licensed Monoclonal Antibody to make and have made, to use, to sell, have sold and offer for sale the Licensed Products and the Licensed Services in the field for the term of this Agreement (collectively the Licenses). Notwithstanding any other provision of this Agreement, (1) Licensee and its Affiliates shall not use the Licensed Cell Line or Licensed Monoclonal Antibody for any purpose other than that expressly described in this Agreement (2) shall not transfer the Licensed Cell Line to any third party or affiliate for any purpose except to a sublicensee as provided in this Agreement and (3) shall in no event transfer the Licensed Cell Line outside of the United States.

Licensee shall have no right or power to grant sublicenses of the Licensed Cell Line, except Licensee shall have the right to sublicense third parties to make the Licensed Monoclonal Antibody on behalf of Licensee solely for the use of Licensee, its affiliates and sublicensees subject to Licensor prior written consent.

License Property
Licensed Cell Line means the hybridoma  cell line BC3 described in Anasetti, C et. al., 'Induction of specific nonresponsiveness in unprimed human T cells by anti-CD3 antibody and alloantigen', J Exp. Med., l 72, pp. 1691-1700 (1990) and Anasetti, C. et al., Treatment of acute graft-versus-host disease with a nonmitogenic anti-CD3 monoclonal antibody, Transplantation, 54, pp. 844~85 1 (1992) and all progeny, clones, derivatives and modifications thereof. Such derivatives and modifications shall not include antibodies which are not derived from or developed using the Licensed Materials and which have been entirely made with the use of information or materials available in the public domain.

Licensed Monoclonal Antibody means the monoclonal antibody BC3 and antigen binding fragments thereof, produced by or derived from the Licensed Cell Line.

Licensed Products means any product, including reagents, devices, kits and packages that contain, or are derived from, or result from the use of the Licensed Monoclonal Antibody including without limitation beads coated with the Licensed Monoclonal Antibody either by itself or in combination with other antibodies. Licensed Products does not include the Licensed Cell Line.

Licensed Services means any service performed for a third party using a Licensed Product or the Licensed Monoclonal Antibody. Services performed on biological materials from a single patient which are clinically defined to constitute a single course of treatment shall constitute the performance of a single Licensed Service procedure for purposes of this Agreement.

Field of Use
IP relates to using the monoclonal antibody that binds to the CD3 molecule for T cell stimulation for ex vivo therapeutic and research uses other than cell separation and selection.  T cells remain in a resting state until they become activated upon encountering antigens expressed by infected cells or tumor cells.

Field means any ex-vivo use for human prophylactic, therapeutic and research applications, excluding cell separation and selection applications.

IPSCIO Record ID: 227238

License Grant
Research License; Supply of Mice; Materials ownership
Licensor hereby grants to Licensee, a Japanese corporation, and the Majority-Owned Affiliates of Licensee, solely as needed to exercise the rights that may be granted, a paid-up, non-exclusive license and/or sublicense of its rights, as the case may be, under the Licensed Technology, without the right to grant further sublicenses, to (i) Breed the XenoMouse Animals included solely for use in the Research Field in connection with activities described in subsections (ii) and (iii) of this Section 2.1.1, (ii) immunize such XenoMouse Animals solely with those Antigens that are Permitted Antigens at the time of immunization and (iii) use the Research Program Materials and Information solely for conducting research and development work within the scope of the Research Field.

Licensor hereby grants to Licensee, and the Majority-Owned Affiliates of Licensee solely as needed to practice the rights that may be granted in accordance with this agreement, a paid-up, non-exclusive license and/or sublicense, as the case may be, of its rights in the Licensor Materials and Information and all intellectual property rights Controlled by Licensor related thereto that are not licensed to Licensee pursuant to the license in subsection (a) above, solely to the extent that the Licensor Materials and Information are necessary or useful to Licensees practice of the license granted in subsection (a) above.

Option to enter into Product License Agreement
Licensor hereby grants to Japanese Licensee an exclusive option (an 'Option') to enter into a Product License Agreement with respect to those Permitted Antigens which have been designated as Product Antigens, as further described. Each calendar year during the term of this Agreement, Licensee may obtain up to Two (2) such Options with respect to Product Antigens, pursuant to the procedures set forth.

License Property
Licensed Technology shall mean the rights Controlled by Licensor in the Licensor Patent Rights and Licensor Know-How; provided, however, that the foregoing shall exclude the Excluded Technology.

Product shall mean (i) with regard to the Option Agreement, any composition which incorporates or is derived from (a) an Antibody that binds to a Product Antigen or (b) Genetic Material encoding such an Antibody, wherein in respect of each Product, said Genetic Material does not encode multiple Antibodies; and (ii) with regard to a Product License Agreement, any composition which incorporates or is derived from (a) an Antibody that binds to the Product Antigen (as defined in such Product License Agreement) or (b) Genetic Material encoding such an Antibody wherein, in respect of each Product, said Genetic Material does not encode multiple Antibodies.

Product Antigen shall mean (i) with regard to the Option Agreement, a Permitted Antigen as to which Licensee has obtained an Option, as further described in the Option Agreement; and (ii) with regard to a Product License Agreement, the Antigen described in the Product License Agreement.

Xenomouse Animals shall mean transgenic mice which are Controlled by Licensor and which contain unrearranged human immunoglobulin genes that are capable of producing human antibodies when immunized with an antigen.

XenoMouseâ„¢ is a leading technology for generating fully human antibody drugs useful in treating a wide range of diseases.

Field of Use
Field shall mean the use of Products (i) for human therapeutic, prophylactic and diagnostic medical purposes and as laboratory research reagen.

XenoMouseâ„¢ is a technology to enable the rapid generation of high affinity, fully human antibody product candidates to essentially any disease target appropriate for antibody therapy.

Research Field shall mean the immunization of XenoMouse Animals with Permitted Antigens, the use of materials derived or generated in whole or in part from such XenoMouse Animals that are so immunized, and the use of the XenoMouse Animals themselves, solely for the creation, identification, analysis, manufacture, research, and preclinical development of Products in the Field. For purposes of clarification, it is understood that 'immunization' of XenoMouse Animals with a Permitted Antigen includes the immunization of XenoMouse Animals with any formulation or construction of a Permitted Antigen, regardless of the three dimensional configuration of such Permitted Antigen, including, but not limited to, cell lines expressing such Permitted Antigen on their cell surface and chimeric molecules containing such Permitted Antigen; provided, however, that any research, development or use of Antibodies that bind to an excluded Antigen (other than to determine whether they bind to a Permitted Antigen) shall be outside of the scope of the licenses granted under the Option Agreement.

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.